Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HLX10 plus chemotherapy versus placebo plus chemotherapy as neoadjuvant/adjuvant treatment for gastric cancer
CTR20191830Phase 3Active
- Sponsor
- HyBioPharma
- Start
- Dec 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of serplulimab in gastric cancer (GC), gastroesophageal junction adenocarcinoma, sponsored by HyBioPharma. Started Dec 2019; status: active.
02
Drugs
serplulimab
03
Conditions
gastric cancer (GC)gastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on CTR20191830.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20191830.